Mr. Tantillo received MPH and MBA degrees from Illinois Benedictine College, and a BS in Mechanical Engineering from Iowa State University.
The polymorphic haptoglobin (Hp) protein is derived from two alleles, 1 and 2, existing at the Hp genetic locus. Three phenotypes linked to the three genotypes, Hp 1-1, Hp 1-2 and Hp 2-2, can be identified using a proprietary ELISA assay being developed by Synvista. In multiple independent prospective longitudinal studies of more than 20,000 individuals, it has been established that the Haptoglobin genotype is an independent risk factor for cardiovascular disease, with a specific relationship to patients with diabetes mellitus. After accounting for conventional cardiovascular risk factors and diabetes characteristics in these studies, research has demonstrated that there is a 2- 5 fold increased risk of cardiovascular disease in people with both diabetes and the Hp 2-2 genotype (approximately 40 percent of all diabetes patients).
Currently, Synvista is developing a proprietary diagnostic test to
determine haptoglobin genotype in order to identify the subset of diabetics
at greatest risk for cardiovascular disease. Since this test is designed to
determine which diabetic patients display the highest levels of oxidative
stress (Hp 2-2 individuals), it can also be used to identify the subset of
diabetics who may benefit most from potent anti-oxidizing agents, such as
SYI- 2074 (previously ALT-2074). The test also
|SOURCE Synvista Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved